AAM
CRSP icon

Advisors Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Advisors Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$877K Buy
16,079
+10,560
+191% +$557K 0.01% 835
2026
Q1 		$263K Sell
5,519
-186
-3% -$9.81K ﹤0.01% 1100
2025
Q4 		$299K Buy
5,705
+1,051
+23% +$62.9K 0.01% 1070
2025
Q3 		$302K Sell
4,654
-585
-11% -$33.6K 0.01% 1060
2025
Q2 		$255K Sell
5,239
-1,646
-24% -$63.7K ﹤0.01% 1079
2025
Q1 		$234K Sell
6,885
-839
-11% -$35.6K ﹤0.01% 1078
2024
Q4 		$304K Sell
7,724
-1,945
-20% -$91.8K 0.01% 1039
2024
Q3 		$454K Buy
9,669
+342
+4% +$17.4K 0.01% 961
2024
Q2 		$504K Sell
9,327
-135
-1% -$7.81K 0.01% 900
2024
Q1 		$645K Buy
9,462
+2,814
+42% +$201K 0.01% 842
2023
Q4 		$416K Sell
6,648
-570
-8% -$31.5K 0.01% 949
2023
Q3 		$328K Buy
7,218
+1,507
+26% +$77.8K 0.01% 1014
2023
Q2 		$321K Sell
5,711
-6,094
-52% -$346K 0.01% 1034
2023
Q1 		$534K Sell
11,805
-100
-0.8% -$4.86K 0.01% 918
2022
Q4 		$484K Sell
11,905
-10,509
-47% -$557K 0.01% 933
2022
Q3 		$1.47M Sell
22,414
-1,481
-6% -$107K 0.03% 595
2022
Q2 		$1.45M Sell
23,895
-3,775
-14% -$222K 0.03% 627
2022
Q1 		$1.74M Sell
27,670
-9,307
-25% -$584K 0.03% 631
2021
Q4 		$2.8M Sell
36,977
-817
-2% -$71.4K 0.04% 490
2021
Q3 		$4.23M Buy
37,794
+3,702
+11% +$465K 0.06% 315
2021
Q2 		$5.52M Buy
34,092
+5,284
+18% +$643K 0.08% 255
2021
Q1 		$3.51M Buy
28,808
+12,024
+72% +$1.82M 0.05% 370
2020
Q4 		$2.57M Buy
16,784
+13,251
+375% +$1.57M 0.04% 441
2020
Q3 		$296K Buy
3,533
+1,636
+86% +$145K 0.01% 1072
2020
Q2 		$139K Buy
+1,897
New +$111K ﹤0.01% 1246

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisors Asset Management's CRSP Position: Q2 2026 in Review

Advisors Asset Management increased its CRISPR Therapeutics (CRSP) stake by 191% in Q2 2026, buying an estimated $557K and bringing the position to 16,079 shares worth $877K. The position accounts for 0.01% of the portfolio, ranked #835.

Advisors Asset Management first reported a position in CRSP in Q2 2020 and has held it in 25 quarters since. The position peaked at $5.52M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Advisors Asset Management held 16,079 shares of CRISPR Therapeutics worth $877K as of Q2 2026.
  • Advisors Asset Management bought 10,560 CRISPR Therapeutics shares in Q2 2026, an estimated $557K.
  • CRISPR Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #835 holding.
  • Advisors Asset Management first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Advisors Asset Management's CRISPR Therapeutics position peaked at $5.52M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.